or preventing cortical membrane reorganization until cytokinesis is completed. Interactions between the actin ring and the spindle midzone and midbody have also been observed in metazoan eukaryotes (2, 31, 32), and microtubules are continuously required to maintain the position of the cleavage furrow and keep nuclei apart during cytokinesis in mammalian cells (33), suggesting that a similar mechanism to the one we have described in fission yeast may operate in other eukaryotes. Insulin resistance is a major hallmark in the development of type II diabetes, which is characterized by the failure of insulin to promote glucose uptake in muscle and to suppress glucose production in liver. The serine-threonine kinase Akt (PKB) is a principal target of insulin signaling that inhibits hepatic glucose output when glucose is available from food. Here we show that TRB3, a mammalian homolog of Drosophila tribbles, functions as a negative modulator of Akt. TRB3 expression is induced in liver under fasting conditions, and TRB3 disrupts insulin signaling by binding directly to Akt and blocking activation of the kinase. Amounts of TRB3 RNA and protein were increased in livers of db/db diabetic mice compared with those in wild-type mice. Hepatic overexpression of TRB3 in amounts comparable to those in db/db mice promoted hyperglycemia and glucose intolerance. Our results suggest that, by interfering with Akt activation, TRB3 contributes to insulin resistance in individuals with susceptibility to type II diabetes.
Insulin resistance is a major hallmark in the development of type II diabetes, which is characterized by the failure of insulin to promote glucose uptake in muscle and to suppress glucose production in liver. The serine-threonine kinase Akt (PKB) is a principal target of insulin signaling that inhibits hepatic glucose output when glucose is available from food. Here we show that TRB3, a mammalian homolog of Drosophila tribbles, functions as a negative modulator of Akt. TRB3 expression is induced in liver under fasting conditions, and TRB3 disrupts insulin signaling by binding directly to Akt and blocking activation of the kinase. Amounts of TRB3 RNA and protein were increased in livers of db/db diabetic mice compared with those in wild-type mice. Hepatic overexpression of TRB3 in amounts comparable to those in db/db mice promoted hyperglycemia and glucose intolerance. Our results suggest that, by interfering with Akt activation, TRB3 contributes to insulin resistance in individuals with susceptibility to type II diabetes.
Under physiological conditions, binding of insulin to its receptor triggers the activation of a phospholipid-dependent kinase cascade that culminates in phosphorylation of the SerThr kinase Akt (also called PKB) (1) . The Akt family of Ser-Thr kinases consists of three highly related family members: Akt1, Akt2, and Akt3. After their recruitment to the plasma membrane in response to growth factor stimulation, all three isoforms are phosphorylated at two conserved residues corresponding to Thr 308 within the active loop and Ser 473 in the regulatory domain of Akt1 (1) . Akt activity appears to be important for glucose homeostasis; mice with a knockout of the Akt2 gene exhibit insulin resistance and glucose intolerance due to elevated hepatic glucose output and reduced glucose uptake in skeletal muscle (2) .
Akt activity is attenuated in part by lipid phosphatases such as PTEN and SHIP, which act upstream of Akt to block its recruitment to the membrane (3) (4) (5) (6) . Akt also appears to be directly dephosphorylated by the Ser-Thr phosphatase PP2A in response to certain stimuli such as hyperosmotic stress (7) . A protein inhibitor, referred to as COOHterminal Akt modulatory protein (CTMP), has been shown to inhibit Akt activity by binding to its COOH-terminal regulatory domain (8), although its effect on insulin signaling has not been determined.
To identify additional proteins that modulate Akt activity, we used a yeast two-hybrid assay to screen for proteins from a preadipocyte F422A cDNA library that interacted with a GAL4-Akt ⌬PH construct lacking the NH 2 -terminal pleckstrin homology domain (amino acids 1 to 145) of Akt1. Twenty-five independent transformants from a screen of 2 ϫ 10 6 cDNAs encoded a 354 -amino acid protein previously identified as neuronal cell deathinducible putative protein kinase (NIPK) (9) and more recently designated in the GenBank database as TRB3. TRB3 and its related family members TRB1 and TRB2 share 45% sequence similarity overall and bear strong resemblance to tribbles, a Drosophila protein that inhibits mitosis early in development by binding to the CDC25 homolog String and promoting its ubiquitination and proteasome-mediated degradation (10) (11) (12) (13) . Like tribbles, TRB family members have a truncated kinase domain that lacks an adenosine 5Ј-triphosphate binding site (GXGXXG) and contains a variant catalytic core motif ( TRB3: amino acids 175 to 182; LRDLKLRR versus consensus: HRDLKPEN). Correspondingly, tribbles and its mammalian counterparts lack detectable kinase activity by in vitro kinase assay (13, 14 ) .
To evaluate the association between Akt1 and TRB3, we performed mammalian two-hybrid assays in 293T cells. Consistent with results from the yeast two-hybrid screen, a GAL4-Akt construct showed no transcriptional activity on its own, but strongly induced GAL4 luciferase reporter activity when cotransfected with TRB3-VP16 expression vector (Fig. 1A) . In vitro-translated 35 S-labeled TRB3 also interacted with baculovirus-expressed glutathione S-transferase (GST)-Akt1 in vitro (Fig. 1B) .
To determine whether endogenous TRB3 and Akt are associated in vivo, we generated a polyclonal antiserum to the NH 2 -terminal 145 amino acids of TRB3, which are not conserved in TRB1 or TRB2. In Western blot assays of HepG2 hepatocyte extracts, antiserum to TRB3 (anti-TRB3) recognized a single band of 45 kD, which is consistent with the predicted molecular size of the protein (Fig. 1C) . Immunoprecipitation of proteins from HepG2 whole-cell extracts with anti-TRB3 revealed a 60-kD band that interacted with anti-Akt ( S1 ). TRB3 was also detected in immunoprecipitates of Akt2, suggesting a more general involvement of TRB3 in regulating cellular Akt activity (14 ) .
In experiments to characterize a relevant Akt interaction domain in TRB3, we identified a variant TRB3 cDNA in the GenBank database that lacks 26 amino acids (amino acids 239 to 265) within the conserved kinase domain. Compared with the wild-type protein, the ⌬TRB3 (⌬) polypeptide interacted more weakly with Akt in coimmunoprecipitation assays ( fig. S1 ). TRB2 was also found to interact with overexpressed Akt in coimmunoprecipitation assays (14) .
Phosphorylation Fig. 2A ). Expression of TRB3 inhibited Akt phosphorylation at both sites without altering total amounts of Akt protein. TRB2 was similarly effective at blocking Akt phosphorylation (14) . Overexpression of TRB3 reduced Akt activity, as determined by in vitro kinase assays with a peptide substrate corresponding to the consensus sequence recognized by Akt (Fig. 2B) . The ⌬TRB3 polypeptide did not inhibit Akt kinase activity. Thus unlike tribbles, which inhibits CDC25 and C/EBP in Drosophila by triggering ubiquitin-mediated proteolysis of these proteins (10-12), TRB3 appears to block Akt activity by disrupting its phosphorylation without reducing the abundance of the protein.
To determine whether the inhibitory action of TRB3 on Akt is physiologically relevant, we disrupted endogenous TRB3 expression in hepatocytes by RNA interference (RNAi). In transient transfection assays, a 21-base pair (bp) TRB3 RNA duplex oligonucleotide reduced the abundance of both endogenous TRB3 and overexpressed Flag-TRB3 protein in a dosagedependent manner (Fig. 2C, fig. S3 ). RNAi-mediated knockdown of TRB3 in HepG2 cells potentiated Akt phosphorylation at Thr 308 and Ser 473 in response to growth factor signaling (Fig. 2C, fig. S4 ). Correspondingly, disruption of TRB3 expression also enhanced phosphorylation of Akt substrates such as GSK3␤ (Ser 9 ) and Foxo (Ser 256 ) in response to insulin and pervanadate, a potent activator of Akt (8) . The effects of TRB3 RNAi appeared to be specific because cotransfection of a mouse TRB3 expression vector, not recognized by the human TRB3 RNAi oligonucleotide used in this study, reversed this phenotype ( fig. S5 ).
To determine the mechanism by which TRB3 may inhibit Akt activity, we performed mammalian two-hybrid assays using TRB3-VP16 expression plasmid and mutant GAL4 Akt constructs. Relative to the wild-type protein, phosphorylationdefective T308A mutant Akt appeared to associate more efficiently with TRB3 (Fig. 2D) . By contrast, substitution of Thr 308 with Asp to mimic Thr 308 phosphorylation strongly inhibited the interaction between TRB3 and Akt (Fig. 2D) , suggesting that TRB3 preferentially binds to the unphosphorylated form of the kinase. Indeed, assays with a series of truncated Akt expression vectors revealed that amino acids 240 to 315 in Akt1 are essential for this association, indicating that TRB3 may block Akt activation by binding directly to and masking the Thr 308 phosphorylation site (Fig. 2D) . Consistent with results from coimmunoprecipitation studies, a GAL4 Akt2 construct interacted with TRB3 in a manner similar to Akt1, suggesting that TRB3 may perform a general role in regulating cellular Akt activity.
The ability of endogenous TRB3 to associate with Akt and to regulate its activity in cultured hepatocytes prompted us to evaluate TRB3 expression in mouse liver under fasting or feeding conditions. In quantitative polymerase chain reaction (PCR) assays, amounts of hepatic TRB3 RNA and protein were 10-to 20-fold higher in organs from fasted animals than in livers from animals that had been refed ( Fig. 3A, left; fig S6) . Amounts of TRB3 RNA and protein were also increased 10-fold in livers from db/db diabetic mice compared with those in livers from wildtype mice (Fig. 3A, right; fig. S6 ). In db/db mice, the change in TRB3 expression was smaller during the fasting-to-feeding transition than that in wild-type mice (Fig. 3A,  right) . Amounts of TRB1 and TRB2 transcripts did not vary with nutritional status (14 ) . Supporting a role for counter-regulatory hormones in stimulating TRB3 expression under fasting conditions, levels of TRB3 RNA were induced two-to threefold in FAO hepatocytes after treatment with either glucocorticoids or cyclic AMP agonist ( fig. S7 ). Taken together, these results suggest that TRB3 could inhibit Akt specifically during fasting, and that inappropriate expression of TRB3 in diabetes may contribute to insulin resistance by blocking Akt activity in the fed state. Indeed, Akt was readily detected in immunoprecipitates of TRB3 prepared from whole-liver extracts from fasted db/db mice, demonstrating that the TRB3:Akt complex is present in liver under fasting conditions ( fig. S8) .
To examine the role of TRB3 in glucose homeostasis in vivo, we infected adult male C57Bl6 mice (n ϭ 7 per group) with TRB3 or control green fluorescent protein (GFP) adenoviruses by tail vein injection and monitored blood glucose levels under fasting and refed conditions. In animals infected with TRB3 adenovirus, amounts of TRB3 RNA and protein in liver were 1.5-to 2-fold higher than those observed in db/db diabetic mice ( fig. S9) (14 ) . Expression of TRB3 had no effect on blood glucose levels in the fasted state (14 ) . By contrast, concentrations of blood glucose levels were increased in the refed state (150 mg/dl versus 115 mg/dl; n ϭ 7), indicating that TRB3 may interfere with acute effects of insulin on hepatic glucose release (Fig.  3B) . Consistent with the notion that TRB3 contributes to insulin resistance, plasma insulin concentrations in the refed state were modestly increased in TRB3-infected mice (2.2 ng/ml) versus GFP control (1.6 ng/ml) mice ( fig. S10) . Indeed, TRB3-overexpressing mice displayed impaired glucose tolerance; after intraperitoneal glucose injection (2 g/kg), their blood glucose levels remained higher than those in control animals (Fig. 3C) . Liver glycogen content in mice infected with TRB3 adenovirus (8 mg/g tissue; n ϭ 4) was twofold lower under feeding conditions than in control mice (16 mg/g tissue; n ϭ 4), suggesting that the hyperglycemic effects of TRB3 may in part reflect elevated hepatic glycogenolysis and/or reduced synthesis (Fig.  3D) .
We also evaluated the role of TRB3 in insulin-dependent glucose metabolism. We used a glucose-output assay on rat FAO hepatoma cells infected with adenovirus constructs expressing either control GFP or TRB3. Glucose release from control cells infected with GFP adenovirus was inhibited 50% after treatment with insulin (10 Ϫ8 M) (Fig. 4A) . But the inhibitory effect of insulin on glucose output was almost completely blocked in cells infected with TRB3 adenovirus (Fig. 4A ). An adenovirus construct expressing the ⌬TRB3 polypeptide had no effect on insulin signaling.
Under physiological conditions, insulin inhibits glycogenolysis by promoting the Akt-dependent phosphorylation of GSK-3␤ at Ser 9 . The dual importance of GSK-3 as a regulator of glucose production and as a bona fide substrate of Akt (15) (16) (17) (18) (19) prompted us to examine whether TRB3-mediated inhibition of Akt correspondingly reduced insulin-dependent phosphorylation of GSK-3. Compared with hepatocytes infected with control GFP adenovirus, cells infected with wild-type TRB3 adenovirus showed reduced insulin-dependent phosphorylation of GSK-3␤ on Ser 9 (Fig. 4B) . But mutant ⌬TRB3 adenovirus had no effect in this regard, indicating that TRB3 interferes with insulin effects on glucose output, at least in part, by blocking phosphorylation of relevant Akt substrates.
Taken together, our results suggest that TRB3 promotes glucose output from liver under fasting conditions by binding to and interfering with Akt phosphorylation in response to residual insulin signaling (Fig. 4C) . Pathological overexpression of TRB3 in the fed state may therefore contribute to insulin resistance and promote hyperglycemia. Our results also provide a potential molecular explanation for the insulin resistance that has been observed under chronic fasting conditions and in response to counter-regulatory hormones like dexamethasone (20) (21) (22) . In this regard, prolonged starvation has been shown to blunt the stimulatory effect of insulin on glycogen synthase activity (23) . And glucocorticoids have been found to promote insulin resistance in adipocytes, in part, by reducing insulin-stimulated Akt activation (24) . The observed expression of TRB3 in response to diabetes and fasting may explain these findings and establish TRB3 as an attractive drug target in the treatment of type II diabetes. 
